Trial reportBMC anesthesiology2026
Application of anterior sciatic nerve block with liposomal bupivacaine in lower leg fracture surgery: a randomized clinical trial.
Trial report in BMC anesthesiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Liposomal Bupivacaine Infiltration and Postoperative Pain Outcomes in Lumbar Fusion: A Prospective Randomized Controlled Trial.Journal of pain research · 2026Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundPostoperative acute pain management remains a critical challenge in orthopedic surgery. This study compared the analgesic efficacy of liposomal bupivacaine versus conventional ropivacaine when administered via an ultrasound-guided anterior sciatic nerve block in patients undergoing lower leg fracture surgery.
methodsIn a randomized, double-blinded trial, eighty adult patients scheduled for elective open reduction and internal fixation (ORIF) of lower leg fractures. Patients were randomized into Group LB (20 mL liposomal bupivacaine, 266 mg) or Group R (20 mL 0.5% ropivacaine). The primary outcome was postoperative pain scores (Visual Analog Scale, VAS) at 6 h (T1), 24 h (T2), 48 h (T3), and 72 h (T4). Secondary outcomes included perioperative opioid use, motor block onset time, Postoperative hospital stay, functional recovery (Barthel Index), and complications.
resultsGroup LB exhibited significantly lower VAS scores at T2 (p < 0.001), T3 (p = 0.007), and T4 (p = 0.042), though with higher scores at T1 (p < 0.001). Postoperative hospital stay was shorter in Group LB (p = 0.021), and functional recovery at discharge (Barthel Index) was superior (p = 0.020). No significant differences in perioperative opioid use or complication rates were observed.
conclusionsCompared to ropivacaine, liposomal bupivacaine administered via anterior sciatic nerve block provided prolonged postoperative analgesia and was associated with improved functional recovery and shorter hospital stay in patients undergoing lower leg fracture surgery.
trial registrationThe study protocol was registered at the Chinese Clinical Trial Registry ( http://www.chictr.org.cn , ChiCTR2400084397, 15/05/2024).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.